homepage-top-section

The investigational maternal vaccine candidate, hexavalent anti capsular polysaccharide (CPS) / cross reactive material 197 glycoconjugate (GBS6) is being developed to help prevent invasive GBS in new-borns. It

Located at the Research Triangle Park (RTP), the facility has nearly 3,300m2 of total gross floor area and will provide additional manufacturing capacity to produce autologous CAR T-cell

Spesolimab is a new selective antibody that inhibits the interleukin-36 receptor (IL-36R) signalling activation. It is claimed to be the first treatment option approved to treat GPP flares.

IPX203 is a new oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules that comprises extended-release (ER) coated beads and immediate-release (IR) granules. The company’s NDA submission is based on

The lipid-peptide analog, OK-101 comprises a 12 amino acid peptide sequence, an anchoring lipid domain, and a linker component. It has been developed using a new membrane-anchored peptide

Scemblix specifically targets the ABL myristoyl pocket, which is also called as a STAMP inhibitor in scientific literature. It provides a new treatment approach for patients experiencing intolerance

Under the terms of the deal, the company will facilitate access to its monkeypox vaccines in Latin America and the Caribbean, as well as the countries that participate

The monoclonal antibody is being investigated to reduce the risk of major thrombotic cardiovascular events in ESRD patients MK-2060 is a new Factor XI inhibitor and has been designed to

The vaccine has been approved for preventing dengue disease in people aged six years to 45 years. Qdenga has been developed based on a live-attenuated dengue serotype 2